Mark Wroblewski
Overview
Explore the profile of Mark Wroblewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oberle R, Kuhrer K, Osterreicher T, Weber F, Steinbauer S, Udonta F, et al.
Life Sci Alliance
. 2022 May;
5(9).
PMID: 35577388
Despite enormous efforts to improve therapeutic options, pancreatic cancer remains a fatal disease and is expected to become the second leading cause of cancer-related deaths in the next decade. Previous...
2.
Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos I, Taverna F, et al.
Cancer Res
. 2018 Apr;
78(12):3220-3232.
PMID: 29674477
Intrinsic and adaptive resistance hampers the success of antiangiogenic therapies (AAT), especially in breast cancer where this treatment modality has proven largely ineffective. Therefore, novel strategies to improve the efficacy...
3.
Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, et al.
Haematologica
. 2018 Mar;
103(6):939-948.
PMID: 29567778
Although inhibitors of bromodomain and extra terminal domain (BET) proteins show promising clinical activity in different hematologic malignancies, a systematic analysis of the consequences of pharmacological BET inhibition on healthy...
4.
Ghiaur G, Wroblewski M, Loges S
Semin Hematol
. 2015 Jun;
52(3):200-6.
PMID: 26111467
Survival of patients with acute myelogenous leukemia (AML) depends on our ability to prevent relapse in patients that achieved complete remission after intensive chemotherapy. While studies focusing on the malignant...
5.
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger J, Janning M, et al.
Oncotarget
. 2015 Apr;
6(8):6341-58.
PMID: 25849942
Anti-angiogenic therapies were approved for different cancers. However, significant primary and secondary resistance hampers efficacy in several tumor types including breast cancer. Thus, we need to develop clinically applicable strategies...
6.
Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, et al.
Blood
. 2013 Aug;
122(14):2443-52.
PMID: 23982172
Acute myeloid leukemia (AML) represents a clonal disease of hematopoietic progenitors characterized by acquired heterogenous genetic changes that alter normal mechanisms of proliferation, self-renewal, and differentiation.(1) Although 40% to 45%...